Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults

Inclusion Criteria: * Males or females between 18 and 50 years, inclusive, who are long-term residents of Gabon. * Good general health as determined by means of the screening procedure. * Assumed availability for the duration of the trial (12 months). * Willingness to participate in the study as evidenced by signing the informed consent document. * Negative for hookworm during screening, or if found to be infected with hookworm, has completed a course of three doses of albendazole. Exclusion Criteria: * Pregnancy as determined by a positive urine hCG (if female). * Participant unwilling to use reliable contraception up until one month following the third immunization (if female and not surgically sterile, abstinent or at least 2 years post-menopausal). * Currently lactating and breast-feeding (if female). * Inability to correctly answer all questions on the informed consent comprehension questionnaire. * Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies. * Known or suspected immunodeficiency. * Laboratory evidence of liver disease (alanine aminotransferase \[ALT\] greater than 1.25-times the upper reference limit). * Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing). * Laboratory evidence of hematologic disease (absolu…